Clinical Development Trends And The Impact On Clinical Trial Technology

Clinical trial activity continues to trend upwards and the biopharmaceutical industry remains strongly committed to investing in R&D despite its inherent risks. Now more than ever, clinical operations teams are turning to technology to simplify processes, like randomization and trial supply, to gain efficiencies and ensure compliance and safety, to ultimately bring therapies to market faster.

Registered trials: 2010 – 2018



217% INCREASE

FDA **23**

New guidance documents the FDA plans to issue on clinical trial design, conduct & reporting in 2018

Locations of recruiting studies

Percentage of registered studies by location*
Total of 279,794 studies



*As of August 1, 2018

Amount spent on R&D by companies covered by Scrip 100

2014 **$138** BILLION

2016 **$157** BILLION

What does this mean for ClinOps teams managing randomization & drug supply for clinical trials using Randomization & Supply Management (RTSM) or Interactive Response Technology (IRT)?

Difficulty keeping up with the fast pace demands of the industry

of respondents said that lack of integration with other clinical platforms was the most common frustration they faced with RTSM

Study changes slow down the process

On average, it **takes 6.5 weeks to build, deploy** and validate a RTSM/IRT solution

92%

of respondents make changes to their RTSM/IRT systems due to study changes

of respondents said changes to inclusion criteria were the most commonly requested mid-study changes

Advances in clinical trials: new data sources and innovations will impact RTSM/IRT processes

50%

of respondents said increasing use of mobile applications will have the most impact on RTSM in the next five years

38%

of respondents said precision medicine will have the most impact on RTSM/IRT in the next five years

If the trends above continue, then we can expect clinical development to continue to rapidly advance as new technologies and innovative approaches to study conduct emerge. In turn, the underlying, foundational technology, like RTSM/IRT, that supports clinical trials will have to innovate to keep up with the demands of the market.

SOURCES:
Scrip | Informa, 2017
ClinicalTrials.gov
CDER 2018 Guidance Agenda
Pharma Intelligence Custom Research on behalf of Oracle Health Sciences | Informa, 2018
Oracle Health Sciences White Paper - RTSM/IRT: A Roadmap For Developing Systems That Address Current Frustrations

Pharma intelligence
informa